BioSpace News Archive

4D Molecular Therapeutics (Nasdaq: FDMT), a clinical-stage gene therapy company harnessing the power of directed evolution for targeted gene therapies, announced new preclinical data from non-human primate (NHP) studies of 4D-150, a dual transgene, intravitreal gene therapy inhibiting four distinct VEGF family members for the treatment of wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME).

The new intravascular technology, called High Frequency Optical Coherence Tomography, was successfully performed on a patient with critical coronary artery disease

Conformis, Inc., an orthopedic medical device company that features personalized knee and hip replacement products, announced that Mark Augusti, Chief Executive Officer, and Bob Howe, Chief Financial Officer, will present at the Canaccord Genuity Musculoskeletal Conference.

Rite Aid announced it is administering COVID-19 vaccines to anyone 12 or older at all locations offering the Pfizer vaccine, following the latest guidance from the Centers for Disease Control and Prevention.

Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a patient-centric, clinical-stage gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system (CNS) in both rare and large patient populations, today announced its participation in a virtual fireside chat at the 2021 RBC Capital Markets Global Healthcare Conference

BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics, today announced financial results for the first quarter of 2021 and provided an update on its business.

Antengene Corporation Limited (“Antengene”, SEHK: 6996.HK), today announced that China’s National Medical Products Administration (NMPA) has approved the Investigational New Drug (IND) application for a Phase III clinical trial designed to evaluate the safety and efficacy of selinexor

Oncology Pharma Inc. Oncology Pharma, Inc. has submitted its initial application to the NASDAQ to begin the process of moving the listing from the Pink Sheets to the Capital Markets Tier of the NASDAQ Exchange.

Lifeloc Technologies, Inc., a global leader in the development and manufacturing of breath alcohol and drug testing devices, has announced financial results for the first quarter ended March 31, 2021.

CTI BioPharma Corp. announced that the Compensation Committee of its Board of Directors granted equity awards to two new employees as equity inducement awards outside of the Company’s Amended and Restated 2017 Equity Incentive Plan and material to the employees’ acceptance of employment with the company.